Result of AGM

Oncimmune Holdings PLC

26 February 2024

 

26 February 2024

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Results of Annual General Meeting

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, announces that at the Company's Annual General Meeting held earlier today all resolutions were duly passed.

The Notice of Annual General Meeting containing the full text of all of the resolutions is available on the Company's website at www.oncimmune.com, the results of the proxy vote on each of the resolutions will also be made available on the Company's website shortly. 

The Company will be holding a general meeting to, amongst other things, receive the Company's annual report for year ended 31 August 2023 ("FY23") and to approve the report on Directors' remuneration for FY23. A further announcement setting out details of this general meeting will be made in due course.

Oncimmune Holdings plc

[e-mail]

Singer Capital Markets (Nominated Adviser and Broker)

Philip Davies, Harry Gooden, James Fischer

[phone]

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

[phone]

[phone]

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com

 

END